Edition:
United States

Fresenius SE & Co KGaA (FREG.DE)

FREG.DE on Xetra

48.74EUR
11:35am EST
Change (% chg)

€-1.38 (-2.75%)
Prev Close
€50.12
Open
€50.00
Day's High
€50.38
Day's Low
€48.74
Volume
2,442,310
Avg. Vol
2,303,104
52-wk High
€71.36
52-wk Low
€38.28

Chart for

About

Fresenius SE & Co KGaA is a Germany-based healthcare group. It operates through four business segments. Fresenius Medical Care runs a global network of dialysis clinics, providing treatment for patients with chronic kidney failure. It also offers dialyzers, dialysis machines and renal pharmaceuticals. Fresenius Kabi specializes... (more)

Overall

Beta: 0.84
Market Cap(Mil.): €27,875.58
Shares Outstanding(Mil.): 556.23
Dividend: 0.80
Yield (%): 1.60

Financials

  FREG.DE Industry Sector
P/E (TTM): 13.78 30.29 35.95
EPS (TTM): 3.64 -- --
ROI: -- 6.28 12.64
ROE: -- 9.14 13.82

Fresenius flags faster earnings growth from 2020 after investment

BERLIN Fresenius expects earnings to grow faster than sales from 2020 after investments to improve its German hospitals and scale up its home dialysis business eat up profit this year, the German healthcare group said on Wednesday.

Feb 20 2019

UPDATE 2-Fresenius flags faster earnings growth from 2020 after investment

* Announces 1 bln euros share buyback at Fresenius Medical Care

Feb 20 2019

Fresenius expects earnings to stagnate in 2019 as investments weigh

BERLIN, Feb 20 German healthcare group Fresenius said sales growth would slow and profit stagnate this year as investments to fix the performance at its German hospitals business and build up home dialysis take a toll.

Feb 20 2019

Akorn gets FDA warning letter for Illinois plant, shares drop

Akorn Inc said on Wednesday it received a warning letter from the U.S. Food and Drug Administration following an inspection of the company's Decatur, Illinois manufacturing plant last year.

Jan 09 2019

UPDATE 3-Akorn gets FDA warning letter for Illinois plant, shares drop

Jan 9 Akorn Inc said on Wednesday it received a warning letter from the U.S. Food and Drug Administration following an inspection of the company's Decatur, Illinois manufacturing plant last year.

Jan 09 2019

Akorn CEO to retire after drugmaker fails to salvage Fresenius merger deal

WILMINGTON, Del Akorn Inc said late on Friday its Chief Executive Officer would retire following the drugmaker's inability to salvage its takeover deal with Germany's Fresenius SE .

Dec 07 2018

Deals of the day-Mergers and acquisitions

Dec 7 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Friday:

Dec 07 2018

UPDATE 2-Fresenius plunges as health firm warns investment to hit profit

* Shares plunge 18 percent, poised for biggest one-day drop (Adds analyst comment, loss in market value)

Dec 07 2018

Fresenius cuts guidance, vows further dividend hikes

FRANKFURT, Dec 7 German healthcare group Fresenius cut its medium-term guidance late on Thursday hurt by lower profit expectations at its dialysis arm FMC and its clinics chain Helios but said that dividends will continue to grow.

Dec 07 2018

Akorn to Delaware justices: Chancery’s MAC opinion is ‘new blueprint for remorseful buyers’

The global pharmaceutical company Fresenius received a rude shock in the summer of 2017 when Akorn, the generic drugmaker Fresenius had agreed to acquire for $4.75 billion, reported its quarterly financial results. The results were terrible – far worse than Fresenius’ gloomiest projection. Fresenius CEO Stephan Sturm considered the Akorn results the biggest personal embarrassment of his career. Within weeks, the company hired Paul Weiss Rifkind Wharton & Garrison to advise it could w

Oct 31 2018

Earnings vs. Estimates